CORERX, INC. ADDS INCREASING PRODUCT DEVELOPMENT CAPACITY Company to Continue Investments, Increase Workforce

CoreRx East

[av_textblock size=” font_color=” color=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=” av_uid=’av-jtdc4pnj’ admin_preview_bg=”] March 18, 2019: Clearwater, Florida – Today CoreRx, Inc. announced plans for continued expansion of its drug product development and manufacturing capabilities in Clearwater, Florida. This expansion will include a 4th facility. The 26,000 sq. ft. facility is adjacent to their existing buildings on the ICOT center campus. The increased R&D development capacity is in response to clients’ demand to provide expert contract services to develop robust, reliable dosage form options. With the new expansion, CoreRx’s clients now have access to over 150,000 square feet of space at the ICOT center campus. The additional expansions should be completed and ready for use by the beginning of Q3 2019 and will include 9 R&D formulation development suites, nearly 5,000 sq. ft. of analytical laboratory space, as well as capacity for 35 additional employees to the Clearwater workforce over time. This new build-out comes on the heels of CoreRx nearing completion of its previous growth efforts in our other three buildings in the ICOT center campus.  This previous build-out consisted of 9 new clinical manufacturing suites and added capacity to our primary and secondary packaging operations, including aggregation and serialization to support niche commercial operations. “This is an exciting time for CoreRx,” said Todd Daviau, president and CEO.“This additional space will allow us to accommodate new equipment and additional headcount to develop and manufacture an ever-expanding range of products for our clients. The new site acquisition and continuing growth are designed to provide the market with a turnkey operation that can support clinical through niche commercial development and manufacturing services while continuing to bolster jobs in the Tampa Bay region.” About CoreRx, Inc. CoreRx, a Contract Development Manufacturing Organization (CDMO) with capabilities to support clinical – niche commercial manufacturing, offering state of the art facilities to support your supply chain needs.  Our integrated offerings provide comprehensive services for the development, manufacturing, and testing of solid, liquid and semi-solid dosage forms. Keep on top of new developments at CoreRx and throughout the drug development industry by following  www.linkedin.com/company/corerx-inc-more detailed information about the company, visit www.corerxpharma.com. For further information, please contact: CoreRx – Marketing Director, Michelle Hall michelle.hall@corerxpharma.com or 727-259-6950 [/av_textblock]